"A US Food and Drug Administration (FDA) advisory panel gave near-unanimous support for approval of the Absorb GT1 bioresorbable vascular scaffold (BVS) system (Abbott Vascular).
If approved, Absorb would be the first drug-eluting coro"...
Papaverine Hydrochloride Injection, USP (papaverine hydrochloride injection) , should not be added to Lactated Ringer's Injection, because precipitation would result.
Papaverine hydrochloride should be used with caution in patients with glaucoma. The medication should be discontinued if hepatic hypersensitivity with gastrointestinal symptoms, jaundice or eosinophilia becomes evident or if liver function test values become altered.
Usage in Pregnancy
Pregnancy Category C - No teratogenic effects were observed in rats when papaverine hydrochloride was administered subcutaneously as a single agent. It is not known whether papaverine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Papaverine hydrochloride should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when papaverine hydrochloride is administered to a nursing woman.
Usage in Children
Safety and effectiveness in children have not been established.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/25/2009
Additional Papaverine Injection Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.